Walleye Capital
DGX icon

Walleye Capital’s Quest Diagnostics DGX Stock Holding History

Walleye Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7K Sell
88
-2,130
-96% -$418K ﹤0.01% 4400
2026
Q1 		$435K Sell
2,218
-13,861
-86% -$2.69M ﹤0.01% 2772
2025
Q4 		$2.79M Buy
16,079
+16,001
+20,514% +$2.91M 0.01% 1592
2025
Q3 		$14.9K Sell
78
-130
-63% -$23.1K ﹤0.01% 4240
2025
Q2 		$37.4K Sell
208
-133
-39% -$23.1K ﹤0.01% 4120
2025
Q1 		$57.7K Sell
341
-3,399
-91% -$558K ﹤0.01% 3805
2024
Q4 		$564K Buy
3,740
+1,479
+65% +$230K ﹤0.01% 2887
2024
Q3 		$351K Sell
2,261
-14,708
-87% -$2.2M ﹤0.01% 3605
2024
Q2 		$2.32M Buy
16,969
+10,423
+159% +$1.43M ﹤0.01% 1964
2024
Q1 		$871K Buy
+6,546
New +$849K ﹤0.01% 2724
2019
Q4 		– Sell
-260
Closed -$28K – 1889
2019
Q3 		$28K Hold
260
– – ﹤0.01% 1695
2019
Q2 		$26K Buy
+260
New +$25K ﹤0.01% 1491

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Walleye Capital's DGX Position: Q2 2026 in Review

Walleye Capital reduced its Quest Diagnostics (DGX) stake by 96% in Q2 2026, selling an estimated $418K and leaving 88 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4400.

Walleye Capital first reported a position in DGX in Q2 2019 and has held it in 12 quarters since. The position peaked at $2.79M in Q4 2025. 1,109 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Walleye Capital held 88 shares of Quest Diagnostics worth $18.7K as of Q2 2026.
  • Walleye Capital sold 2,130 Quest Diagnostics shares in Q2 2026, an estimated $418K.
  • Quest Diagnostics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4400 holding.
  • Walleye Capital first reported a position in Quest Diagnostics in Q2 2019 and has held it in 12 quarters since.
  • Walleye Capital's Quest Diagnostics position peaked at $2.79M in Q4 2025.
  • 1,109 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.